JPH0478295B2 - - Google Patents
Info
- Publication number
- JPH0478295B2 JPH0478295B2 JP63222954A JP22295488A JPH0478295B2 JP H0478295 B2 JPH0478295 B2 JP H0478295B2 JP 63222954 A JP63222954 A JP 63222954A JP 22295488 A JP22295488 A JP 22295488A JP H0478295 B2 JPH0478295 B2 JP H0478295B2
- Authority
- JP
- Japan
- Prior art keywords
- blood
- sensor
- infusion
- heparin
- flow cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004369 blood Anatomy 0.000 claims description 37
- 239000008280 blood Substances 0.000 claims description 37
- 239000000126 substance Substances 0.000 claims description 28
- 239000000306 component Substances 0.000 claims description 21
- 239000012503 blood component Substances 0.000 claims description 16
- 210000004204 blood vessel Anatomy 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 11
- 239000003146 anticoagulant agent Substances 0.000 claims description 9
- 229960004676 antithrombotic agent Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 description 31
- 238000001802 infusion Methods 0.000 description 25
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 19
- 229960002897 heparin Drugs 0.000 description 19
- 229920000669 heparin Polymers 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 14
- 238000005259 measurement Methods 0.000 description 13
- 125000001453 quaternary ammonium group Chemical group 0.000 description 12
- 238000012545 processing Methods 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 239000006087 Silane Coupling Agent Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229910044991 metal oxide Inorganic materials 0.000 description 3
- 150000004706 metal oxides Chemical class 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000005669 field effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical group CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012482 calibration solution Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XTAKDLWEWPRLGB-UHFFFAOYSA-N dimethyl-octadecyl-(3-trimethoxysilylpropyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCC[Si](OC)(OC)OC XTAKDLWEWPRLGB-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- SBHRWOBHKASWGU-UHFFFAOYSA-M tridodecyl(methyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(CCCCCCCCCCCC)CCCCCCCCCCCC SBHRWOBHKASWGU-UHFFFAOYSA-M 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
Landscapes
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63222954A JPH0268039A (ja) | 1988-09-05 | 1988-09-05 | 血液成分測定装置 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63222954A JPH0268039A (ja) | 1988-09-05 | 1988-09-05 | 血液成分測定装置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0268039A JPH0268039A (ja) | 1990-03-07 |
| JPH0478295B2 true JPH0478295B2 (fr) | 1992-12-10 |
Family
ID=16790482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63222954A Granted JPH0268039A (ja) | 1988-09-05 | 1988-09-05 | 血液成分測定装置 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0268039A (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9806966D0 (en) * | 1998-03-31 | 1998-06-03 | Ppl Therapeutics Scotland Ltd | Bioloically modified device |
-
1988
- 1988-09-05 JP JP63222954A patent/JPH0268039A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0268039A (ja) | 1990-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0657030B1 (fr) | Solutions d'etalonnage utilisees dans les analyses de fluides biologiques et leur procede d'utilisation | |
| JPH0554979B2 (fr) | ||
| JPS63181738A (ja) | 流動媒体の検査装置およびその作動方法 | |
| EP0958499B1 (fr) | Procede pour etalonner des capteurs utilises dans les tests de diagnostic | |
| US3512517A (en) | Polarographic method and apparatus for monitoring blood glucose concentration | |
| JPH04341241A (ja) | 体液成分測定方法および測定装置 | |
| US20090134043A1 (en) | Non-biofouling, universal redox electrode and measurement system | |
| Rolfe | In vivo chemical sensors for intensive-care monitoring | |
| Sibbald et al. | Online patient-monitoring system for the simultaneous analysis of blood K+, Ca 2+, Na+ and pH using a quadruple-function ChemFET integrated-circuit sensor | |
| ES2372252T3 (es) | Método para reducir la tasa de pérdida de oxígeno de soluciones acuosas. | |
| JPH0478295B2 (fr) | ||
| US4743352A (en) | Sodium ion-selective electrode system and method for making an ion-selective electrode | |
| JPH0765978B2 (ja) | 微量成分測定方法及び微量成分測定装置 | |
| Gfrerer et al. | Novel system for real-time ex vivo lactate monitoring in human whole blood | |
| Nakamura et al. | Online pH, p CO 2 and p O 2 monitoring system using two-way cyclic pumping of lactate Ringer as a baseline solution | |
| Zhang et al. | Improved performance of intravascular pO 2 sensor incorporating poly (MPC-co-BMA) membrane | |
| JPS6317448B2 (fr) | ||
| Heidrich et al. | Continuous Analysis in Extracorporeally Circulating Blood-A Rat Model Applying Flow-Through Ion-Selective Electrodes for the Measurement of Ca2+, K+, Na+ and pH | |
| JPH0368692B2 (fr) | ||
| JP4495975B2 (ja) | リバースイオントフォレーシスによって血中尿素濃度を測定する方法 | |
| Rolfe | Intravascular, tissue and ex-vivo sensors for anaesthesia and critical care | |
| JP3926658B2 (ja) | 糖検出装置及び糖検出方法 | |
| JPH0244725Y2 (fr) | ||
| Regnault et al. | Electronic materials in biological applications | |
| Gfrerer et al. | Continuous ex vivo lactate monitoring in whole blood |